ClinicalTrials.gg
Active, not recruitingNCT05948475FIRST-308Updated Jul 6, 2026

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

A Phase 3 interventional study of Tinengotinib 8 mg and Tinengotinib 10 mg in Cholangiocarcinoma, sponsored by TransThera Sciences (Nanjing), Inc.. Active, not recruiting at 87 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by TransThera Sciences (Nanjing), Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Planned enrollment
39th of 279
200 · median 44
Started
2023
with 20 others
Phase 3
18 of 328
3 open now
Primary completion
2026-12
later than 25 of 110 live
Registered
259th of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 39th largest by planned enrollment of the 279 interventional ones that give a count, is one of 21 that started in 2023, is one of 18 in phase 3, reaches primary completion later than 25 of the 110 other live ones, and was the 259th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 287 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma

Read the detailed description

Approximately 200 subjects will be enrolled. Eligible subjects will be randomized in a 2:2:1 ratio to receive tinengotinib 8 mg QD, tinengotinib 10 mg QD or Physician's Choice in Part A; and eligible subjects will be randomized in a 2:1 ratio to receive the recommended Part B dose or selected dose or Physician's Choice in Part B.

03

Conditions studied

  • Cholangiocarcinoma

Browse trials for

Keywords

  • Refractory/Relapsed Cholangiocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age at the time of signing the form (ICF).
  2. or cytologically confirmed CCA/adenocarcinoma of biliary origin with radiological evidence of unresectable or disease.
  3. Documentation of FGFR2 fusion/rearrangement gene status
  4. Subjects must have received at least one and exactly one FDA approved FGFR inhibitor.

Exclusion criteria

Exclusion Criteria:

  1. Prior receipt of two or more FGFR inhibitors, either approved or drugs.
  2. Subjects with known brain or central nervous system (CNS) that have radiologically or clinically progressed in the 28 days prior to initiation of therapy. Subjects with asymptomatic brain/ or treated brain/CNS metastases that have been clinically stable for 14 days on without escalation of steroids are eligible for enrollment.
  3. Subjects with a known concurrent that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, including those that have previously undergone potentially curative therapy.
  4. Subjects who have received prior systemic therapy or investigational study drug ≤ 5 half-lives or 14 days, whichever is shorter, prior to starting the study drug or who have not recovered (grade ≤ 1 or at pretreatment baseline except tolerable grade 2 alopecia, fatigue/asthenia, and neuropathy due to trauma) from adverse events (AEs) of prior therapy.
  5. Concurrent anticancer therapy including chemo-, immune-, or radiotherapy. Hormone therapy may be allowed with Sponsor approval.
  6. Subjects who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting the study drug or who have not recovered from AEs of prior therapy.
  7. Subjects with uncontrolled hypertension (defined as blood pressure of ≥ 150 mm Hg systolic and/or ≥ 90 mm Hg diastolic despite adequate treatment with antihypertensive medications at screening)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Tinengotinib 8 mg QD

    Tinengotinib will be administered in 28-day cycles.

    Drug: Tinengotinib 8 mg

  • Experimental
    Tinengotinib 10 mg QD

    Tinengotinib will be administered in 28-day cycles.

    Drug: Tinengotinib 10 mg

  • Active comparator
    Physician's Choice

    Physician's Choice treatments include FOLFOX or FOLFIRI

    Drug: Physician's Choice

Interventions

  • Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.

  • Subjects randomized to receive tinengotinib will receive a starting dose of either10 mg QD., self-administered orally QD in 28-day cycles.

  • DrugPhysician's Choice

    For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Part A: Incidence, duration, and severity of adverse events (AEs)

    As assessed per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (or the most current version).

    Time frame: Up to 30 days from study discontinuation

  2. Part B: PFS by BICR

    Progression-free survival (PFS) by BICR: PFS is defined as the time from date of randomization to the date of first documented disease progression as assessed by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or date of death due to any cause, whichever is earlier.

    Time frame: From first study drug administration until the date of first documented progression assessed by BICR or date of death from any cause, whichever came first, assessed up to 24 months

Secondary outcomes

  1. Part A: ORR by Investigator

    ORR:objective response rate (ORR), the proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months.

  2. Part A: DOR by Investigator

    Duration of response for CR or PR based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months.

  3. Part B:Overall Survival (OS)

    OS is defined as the time from date of randomization to date of death of any cause.

    Time frame: From first study drug administration until the date of death from any cause, assessed up to 24 months.

  4. Part B: Objective Response Rate (ORR) by BICR and by Investigator:

    The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months.

  5. Part B: Duration of Response (DOR) by BICR and by Investigator

    Duration of response for CR or PR based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months.

  6. Part B: PFS by Investigators per RECIST v1.1.

    PFS is defined as the time from date of randomization to the date of first documented disease progression as assessed by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: From first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

07

Study locations

87 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 17, 2023
StartActual
Dec 20, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05948475
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Jul 17, 2023
Start date
Dec 20, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Milind Javle, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinengotinib

Start the discussion